BIOA
BioAge Labs, IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$777.98M
P/E Ratio
—
EPS
$-2.24
Beta
—
52W High
$24.00
52W Low
$2.88
50-Day MA
$19.60
200-Day MA
$10.64
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About BioAge Labs, Inc
BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various customers in the chemical market primarily in the United States and Canada. The company is headquartered in Montreal, Canada.
Fundamentals
| Revenue (TTM) | $8.99M |
| Gross Profit (TTM) | $-64.97M |
| EBITDA | $-92.57M |
| Operating Margin | -923.00% |
| Return on Equity | -27.10% |
| Return on Assets | -17.80% |
| Revenue/Share (TTM) | $0.25 |
| Book Value | $7.28 |
| Price-to-Book | 2.85 |
| Price-to-Sales (TTM) | 86.49 |
| EV/Revenue | 55.71 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $44.38M |
| Float | $37.01M |
| % Insiders | 2.43% |
| % Institutions | 61.16% |
Analyst Ratings
Consensus ($53.33 target)
2
Strong Buy3
Buy2
HoldData last updated: 4/7/2026